Durvalumab, an Anti-PD-L1 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer

Therapuetic Areas:Oncology
Age Range:18 - Any
Start Date:November 2016
End Date:November 2020
Contact:Geoffrey Ku, MD

Use our guide to learn which trials are right for you!

Phase II Study of Induction Chemotherapy and Durvalumab (MEDI4736) With Chemoradiation for Esophageal and Gastroesophageal Junction Adenocarcinoma

The purpose of this study is to test the safety of adding a new drug, durvalumab (also called
MEDI4736), to chemoradiation with either FOLFOX/Capeox or carboplatin and paclitaxel,
following initial chemotherapy with FOLFOX. The investigators want to find out what effects,
good and/or bad, this combination has on the patient and cancer.

Inclusion Criteria:

- Histologically or cytologically confirmed adenocarcinoma of the esophagus or
gastroesophageal junction (GEJ). Pathology must be confirmed at Memorial Sloan
Kettering Cancer Center

- Tumors that are Her2 positive are eligible

- Availability of archived tumor tissue for banking

- TanyN+M0 or T3-4NanyM0 tumors

- Disease must be clinically limited to the esophagus or GEJ. GEJ tumors must be Siewert
Type I-III

- No prior chemotherapy

- Prior radiation is permitted, provided it does not limit the ability to deliver
per-protocol radiation in the opinion of the treating radiation oncologist

- Patients must have surgically resectable disease treatable by esophagectomy, as
assessed by a thoracic surgeon

- Patients must be ≥18 years of age

- Eastern Cooperative Oncology Group performance status of 0-1

- Female subjects must either be of non-reproductive potential (i.e. post-menopausal by
history: ≥60 years old and no menses for ≥1 year without an alternative medical cause;

- OR history of hysterectomy, OR history of bilateral tubal ligation, OR history of
bilateral oophorectomy) or must have a negative serum pregnancy test upon study entry

- Adequate organ function defined at baseline as:

- WBC ≥3,000/ L

- ANC ≥1,500/ L

- Platelets ≥100,000/ L

- Hb ≥9 g/dl

- Calculated creatinine clearance >40 ml/min using Cockcroft-Gault method:


Creatinine CL = Weight (kg) x (140 - Age) . (mL/min) 72 x serum creatinine (mg/dL)


Creatinine CL (mL/min) = Weight (kg) x (140 - Age) x 0.85 72 x serum creatinine (mg/dL)

- Total serum bilirubin ≤1.5 mg/dL

- AST/ALT ≤2.5× upper limit of normal

- Mean QT interval corrected for heart rate (QTc) <470 ms calculated from 3 ECGs
using Frediricia's Correction

- Able to provide written informed consent

- Subject willing to provide informed consent for MSKCC IRB#12-245 for IMPACT

- Subject is willing and able to comply with the protocol for the duration of the
study including undergoing treatment and scheduled visits and examinations
including follow up

Exclusion Criteria:

- Carcinoma in-situ and tumors determined to be T1-2N0

- Tumors with significant involvement of the proximal stomach which, in the opinion of
the treating thoracic surgeon, would require an esophagogastrectomy

- Patients with evidence of metastatic disease, including:

- Positive malignant cytology of the pleural, pericardium or peritoneum

- Radiographic evidence of distant organ involvement

- Non-regional lymph nodes that cannot be contained within a radiation field

- Biopsy-proven tumor invasion of the tracheobronchial tree or presence of
tracheoesophageal fistula. Recurrent laryngeal or phrenic nerve paralysis

- Grade 2 ≥ peripheral neuropathy

- Active or prior documented autoimmune or inflammatory disorders (including
inflammatory bowel disease; systemic lupus erythematosus; Wegener syndrome
[granulomatosis with polyangiitis]; myasthenia gravis; Graves' disease; rheumatoid
arthritis, hypophysitis, uveitis) within the past 3 years prior to the start of
treatment. The following are exceptions to this criterion:

- Subjects with vitiligo or alopecia

- Subjects with hypothyroidism (e.g., following Hashimoto syndrome) stable on
hormone replacement or psoriasis not requiring systemic treatment

- History of pneumonitis

- The use of immunosuppressive medication within 28 days prior to the first dose of
durvalumab. The following are exceptions to this criterion:

- Intranasal, topical, inhaled corticosteroids or local steroid injections (e.g.
intraarticular injection)

- Systemic corticosteroids at physiologic doses ≤10 mg/day of prednisone or

- Steroids as premedication for hypersensitivity reactions (e.g. CT scan

- Known HIV positivity

- Chronic Hepatitis B or known Hepatitis C infection (e.g. Hepatitis B surface Ag
positive or detectable viral load for Hepatitis B). Patients with prior evidence of
Hepatitis B or C without active infection are eligible

- Known history of previous clinical diagnosis of tuberculosis

- Uncontrolled seizures

- Pregnant or breast-feeding women. Women of childbearing potential (WOCBP) must undergo
a negative pregnancy test (either serum or urine) prior to study entry. Male and
female patients of reproductive potential need to employ two highly effective and
acceptable forms of contraception throughout their participation in the study and for
90 days after last dose of study drug. WOCBP include:

- Any woman who has experienced menarche and who has not undergone surgical
sterilization (hysterectomy, bilateral tubal ligation or oophorectomy) or who is
not post-menopausal (defined as amenorrheic ≥12 consecutive months)

- Women on hormone replacement therapy with documented serum follicle stimulating
hormone level > 35 mIU/ml

- Women who are using oral, implanted or injectable contraceptive hormones or
mechanical products such as intrauterine device or barrier methods to prevent
pregnancy or are practicing abstinence of where the partner is sterile

- Prior malignancy (other than basal cell/squamous cell carcinoma of the skin, in-situ
cervical carcinoma or superficial transitional cell bladder carcinoma) diagnosed
and/or treated within three years of study entry

- Connective tissue disorders, e.g. scleroderma, that in the opinion of the treating
physicians is a contraindication to radiation therapy

- History of primary immunodeficiency

- History of allogenic organ transplant

- Receipt of live attenuated vaccination within 30 days prior to study entry or within
30 days of receiving durvalumab. For example, the intramuscular influenza vaccine can
be administered but the intranasal vaccine is a live attenuated virus that cannot be

- Any previous treatment with a PD1 or PD-L1 inhibitor, including durvalumab

- History of hypersensitivity to durvalumab or any excipient Uncontrolled intercurrent
illness including but not limited to, ongoing or active infection, symptomatic
congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac
arrhythmia, active peptic ulcer disease, active bleeding diatheses or psychiatric
illness/social situations that would limit compliance with study requirements or
compromise the ability of the subject to give written informed consent
We found this trial at
Basking Ridge, New Jersey 07920
Phone: 646-888-4588
Basking Ridge, NJ
Click here to add this to my saved trials
Commack, New York 11725
Phone: 646-888-4588
Commack, NY
Click here to add this to my saved trials
500 Westchester Avenue
Harrison, New York 10604
Phone: 646-888-4588
Harrison, NY
Click here to add this to my saved trials
1275 York Ave
New York, New York 10021
(212) 639-2000
Principal Investigator: Geoffrey Ku, MD
Phone: 646-888-4588
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
New York, NY
Click here to add this to my saved trials
Rockville Centre, New York 11570
Phone: 646-888-4588
Rockville Centre, NY
Click here to add this to my saved trials
Uniondale, New York 11553
Phone: 646-888-4588
Uniondale, NY
Click here to add this to my saved trials